Need help with ordering? Contact us at 1-877-468-3832

TANOVEA-CA1 lymphoma treatment for dogs

Cancer Bites
Bite back with TANOVEA-CA1

The first FDA conditionally approved lymphoma treatment specifically for dogs.

Designed to target and kill lymphoma cells

  • Promotes anti-tumor activity in as few as 7-21 days for canine lymphoma

Easy to Administer

  • Dosing once every three weeks, for us to five doses
  • Simple, 30-minutes intravenous infusion of 1 mg/kg

Effective

  • 77% overall response rate
  • 134 day overall median progression-free survival time  (PFS) in responding dogs
  • Effective in the re-induction setting

Generally well-tolerated in clinical studies

  • The majority of adverse reactions were Veterinary Cooperative Oncology Group (VCOG) 5 grade 1-2
  • Most adverse reactions resolved either spontaneously, with supportive treatment, dose modifications, or dose delays

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-475. CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.

SaveSave